Diffuse Large B-Cell Lymphoma — Trials

Diffuse Large B-Cell Lymphoma — Trials · CancerIndex

Clinical trials

Registered studies

1,150 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 355
Recruiting: 190
Ph III recruiting: 16
Growth YoY: −11.6%
Industry share: 26%
Top sponsor: National Cancer Institute (NCI)
Termination share: 38.2%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (177)

clinicaltrialsPublishedShowing 1–2 of 2 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05733650	Expanded Access Program for Epcoritamab	approved for marketing	—	—	GenmabINDUSTRY	0	May 25, 2023	clinicaltrials
NCT04300803	Expanded Access Program for Tafasitamab (MOR00208) in R/R DLBCL	approved for marketing	—	—	MorphoSys AGINDUSTRY	0	Aug 28, 2020	clinicaltrials